Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study Of ISIS 681257 Subcutaneous Injections In Male And Female Subjects With Normal And Impaired Renal Function

NCT03506854 is registered in ClinicalTrials.gov with Akcea Therapeutics as lead sponsor.

NCT NCT03506854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03506854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study Of ISIS 681257 Subcutaneous Injections In Male And Female Subjects With Normal And Impaired Renal Function
Lead sponsor
Akcea Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
March 20, 2018
Completion date
October 11, 2018
Enrollment
16 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment